In conclusion, the molecular chaperone activity of PRDX1 to bind to CUL2 was at least as important as the peroxidase activity, providing new insights into the role of PRDX1 for drug design to inhibit CRC progression by modulating anti‐tumor immunity. The gene discussed is CUL2; the disease is neoplasm.